Evaluation of an ELISA for FIV antibodies: limitations and indirect relevance to FeLV
Veterinary sciences · 2025
In plain language
This laboratory study evaluated a test that detects antibodies to feline immunodeficiency virus (FIV), not FeLV. It did not extensively examine whether the test can react with other components in samples, and whether severe inflammation or immune system activation can interfere with the result remains unknown. The authors note that an insufficient antibody response early in infection or severely weakened immune defenses in advanced stages may produce negative results despite FIV infection, but this study did not demonstrate those possibilities. The results do not establish how FeLV tests perform or what happens to cats with FeLV.
Scientific detail
The study published in Veterinary sciences in 2025 (doi: 10.3390/vetsci12020089) evaluated FIVCHECK Ab ELISA in vitro using feline serum/plasma samples. The assay uses a recombinant antigen derived from FIV gp40, which the authors describe as immunodominant during FIV infection. This immunodominance is cited background, not a result of immune-response experiments conducted in this study, and does not establish an analogous antigen target for FeLV.
Development and validation were reported to involve 115 samples: 38 FIV-antibody-positive and 77 negative. Comparisons with commercial ELISAs included 103 samples: 28 positive and 75 negative. The cut-off evaluation separately reported 103 samples, comprising 37 positive and 66 negative. The number of unique cats was not reported. Validation used another antibody assay as the reference rather than independently established infection status.
The authors did not perform extensive cross-reactivity studies because representative samples were lacking. Potential interference in cats with profound inflammation or immune activation remains unexplored; this does not demonstrate that inflammation causes interference or that cross-reactivity is absent. Drawing on cited literature, the authors also identify insufficient early antibody responses and severe late-stage immunosuppression as possible causes of false-negative FIV antibody results. The study did not demonstrate these possibilities in clinically staged cats, quantify that risk, or establish the same behavior for FeLV assays.
Information on breed, sex, age, clinical outcomes, disease progression, and drug treatment was unavailable. The authors acknowledge the lack of a real-world study. In addition, the supplied text omits part of the methods and results and does not include the referenced tables or supplementary data. Although the comparator includes a FeLV p27 antigen component, the reported validation concerns FIV antibodies. All three statements are classified as level D evidence because of their indirect relevance to FeLV: they raise antibody-response and cross-reactivity issues that may motivate separate investigation, but do not establish FeLV diagnostic performance, mechanisms of immunosuppression, or outcomes.
What we know
FIVCHECK Ab ELISA uses a recombinant antigen derived from FIV gp40 and was evaluated in vitro in feline samples, with another antibody assay as the reference. The immunodominance of gp40 and the possible causes of false-negative results discussed are cited background, not new immunological findings from this study. Cross-reactivity assessment was not extensive. Relevance to FeLV is indirect, with level D evidence.
What we don't know
Cross-reactivity has not been comprehensively established, nor has it been determined whether profound inflammation or immune activation interferes with the assay. This study does not quantify the risk of false-negative results associated with the stage of FIV infection or provide validation in real-world conditions or against independently established infection status. The number of unique cats is unknown, and demographic and clinical data are missing, as are parts of the text, the tables, and supplementary data. FeLV diagnostic performance, mechanisms of immunosuppression, and outcomes are not established.
Evidence
EvidenceLevel D — Indirect evidence: other species or retrovirusConfidence 100/100
FIVCHECK Ab ELISA uses a recombinant antigen derived from FIV gp40, which the authors describe as immunodominant in FIV infection.
Excerpt verified in the source — verbatim, in the source's own language“However, FIVCHECK Ab ELISA uses only a recombinant antigen derived from envelope transmembrane glycoprotein gp40 because it is considered the immunodominant protein in FIV infection, instead of p15 and p24, which may be less specific for FIV and may be the result of infection with other viruses [ 42 ];”
This states the antigen-selection rationale for an FIV antibody assay. Immunodominance is cited background, not newly demonstrated by immune-response experiments here. It does not establish an analogous antigen target for FeLV; level D reflects its indirect relevance to FeLV.
EvidenceLevel D — Indirect evidence: other species or retrovirusConfidence 100/100
The study did not extensively assess cross-reactivity, and the authors identify potential assay interference in cats with profound inflammation or immune activation as unresolved.
Excerpt verified in the source — verbatim, in the source's own language“However, the presence of ELISA-interfering substances, including drugs or natural compounds, in the blood of cats with profound inflammation or immune activation should be explored. In this regard, we did not perform extensive studies to verify cross-reactivity reactions, partly due to a lack of representative samples, which are difficult to find.”
This is an explicit limitation of the FIV assay evaluation. It does not demonstrate that inflammation causes interference, nor that cross-reactivity is absent. Level D denotes indirect relevance to FeLV rather than a FeLV-specific experiment.
EvidenceLevel D — Indirect evidence: other species or retrovirusConfidence 100/100
The authors identify insufficient early antibody responses and severe late-stage immunosuppression as possible causes of false-negative FIV antibody results.
Excerpt verified in the source — verbatim, in the source's own language“Regarding false negative results, they may occur early in the disease before there is a sufficient antibody response or late in the disease when the cat is severely immunosuppressed [ 49 ].”
This is a cited FIV diagnostic caveat, not a finding demonstrated in clinically staged cats in this study. It does not quantify false-negative risk or establish the same behavior for FeLV assays.
Provenance
Source: A New Rapid Indirect ELISA Test for Serological Diagnosis of Feline Immunodeficiency.
AVA